Pharmaceutical Technology

MAY 23, 2023

The US Food and Drug Administration (FDA) has granted approval for Blueprint Medicines’ Ayvakit (avapritinib) as the first and only treatment for indolent systemic mastocytosis (ISM) in adult patients. The precision therapy has been designed for potently and selectively inhibiting KIT D816V, which is the main underlying driver of the disease.

FDA Approval 246

FDA Approval Medicine Drugs Trials 246

Bio Pharma Dive

OCTOBER 24, 2023

Rampart Biosciences closed a Series A round that will fund its goal to develop more potent DNA-based medicines that avoid immune responses.

DNA 267

DNA Medicine Immune Response Development 267

Pharmaceutical Technology

OCTOBER 12, 2023

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has published updated guidance on valproate-containing medicines.

Medicine 147

Medicine Containment Production 147

Pharmaceutical Technology

NOVEMBER 8, 2023

NICE is also working on incorporating real-world and AI-generated evidence into medicine evaluation submissions.

Medicine 147

Medicine 147

Bio Pharma Dive

SEPTEMBER 22, 2023

Results show that the medicine helped patients who progressed on earlier-line treatments live longer than those receiving chemotherapy without their disease getting worse, according to a Friday announcement.

Medicine 169

Medicine 169

Pharmaceutical Technology

DECEMBER 23, 2022

Eli Lilly and Company has expanded a licencing and partnership agreement with ProQR Therapeutics to discover, develop and market new genetic medicines. The post Lilly and ProQR to expand genetic medicine development agreement appeared first on Pharmaceutical Technology.

Genetics 328

Genetics Medicine Gene Therapy Development 328

Pharmaceutical Technology

OCTOBER 25, 2023

A blockchain system intended to ensure the safety and authenticity of medicines across the supply chain could change the way that medical professionals work, as discussed at the 11th Annual Clinical Trial Supply Nordics conference.

Medicine 130

Medicine Clinical Trials Clinical Trials Trials 130

Pharmaceutical Technology

JUNE 8, 2023

Biotechnology company Hopewell Therapeutics has raised $25m in seed financing to accelerate the development of next-generation lipid nanoparticles for targeted delivery of genomic medicines. Hopewell Therapeutics is engaged in discovering, synthesising and developing advanced ttLNPs to provide next-generation genomic medicines.

Genome 130

Genome Genomics Medicine Genetic Disease 130

JAMA Internal Medicine

NOVEMBER 19, 2023

This cross-sectional study examines the provenance and clinical benefit of medicines that entered the French market between 2008 and 2018 using the Prescrire and Haute Autorité de Santé grading systems.

Medicine 86

Medicine Marketing 86

pharmaphorum

NOVEMBER 17, 2023

Frontiers Health 2023: Hakim Yadi, Closed Loop Medicine Mike.Hammerton Fri, 17/11/2023 - 12:00 Bookmark this

Medicine 126

Medicine 126

Pharmaceutical Technology

FEBRUARY 27, 2023

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the refusal of the marketing authorisation for Me rck and Ridgeback Biotherapeutics’ Lagevrio (molnupiravir).

Medicine 162

Medicine Trials Regulation Research 162

Pharmaceutical Technology

AUGUST 2, 2023

Revolution Medicines has signed a definitive agreement to acquire biopharmaceutical company EQRx in an all-stock transaction.

Medicine 130

Medicine 130

Pharmaceutical Technology

JUNE 20, 2023

The Department of Health Abu Dhabi (DoH) has signed a memorandum of understanding with integrated healthcare company M42 and AbbVie Biopharmaceuticals to advance personalised medicine and genomics in the city. M42 was created through the combination of Mubadala Health and G42 Healthcare.

Medicine 130

Medicine Genome Genomics Clinical Trials 130

Pharmaceutical Technology

JANUARY 3, 2023

Blacksmith Medicines has signed a definitive merger agreement with Forge Therapeutics to create a combined entity that will discover and develop medicines targeting a large class of proteins called metalloenzymes. The merged entity will focus on developing medicines with an initial focus on oncology and infection.

Medicine 130

Medicine Genome Genomics DNA 130

BioPharma Reporter

NOVEMBER 21, 2023

A partnership combining an integrated drug creation platform with a company specializing in dermatological expertise will deliver life-changing medicines to patients.

Medicine 97

Medicine Dermatology Drugs Regulation 97

Pharmaceutical Technology

JULY 28, 2023

Carmell Therapeutics has entered a definitive agreement and plan of merger with the regenerative medicine company Axolotl Biologix.

Medicine 130

Medicine 130

Outsourcing Pharma

NOVEMBER 24, 2023

Calliditas Therapeutics AB announced today (November 24) that its partner Everest Medicines has revealed that China's National Medical Products Administration (NMPA) has approved Nefecon.

Medicine 84

Medicine Drugs Production Regulation 84

Pharmaceutical Technology

MARCH 24, 2023

Moderna has entered a strategic partnership with Generation Bio for the development of non-viral genetic medicines. Moderna’s biological and technical expertise will be combined with core technologies of the non-viral genetic medicine platform from Generation Bio.

Genetics 130

Genetics Medicine Development In-Vivo 130

Pharmaceutical Technology

JUNE 19, 2023

Oral liquid medicine manufacturer Rosemont Pharmaceuticals has announced the acquisition of Lucis Pharma. Rosemont believes this acquisition will allow it to enter the single-use sachet pharmaceutical market, expanding its liquid medicines portfolio in a growing market.

Medicine 130

Medicine Manufacturing Nurses Marketing 130

Pharmaceutical Technology

NOVEMBER 1, 2022

Intrinsic Medicine has signed a definitive business combination agreement with special purpose acquisition (SPAC) firm Phoenix Biotech Acquisition to create a public company. To be named Intrinsic Medicine following closing, the combined company will be led by current Intrinsic CEO Alexander Martinez and president and COO Jason Ferrone.

Medicine 147

Medicine Clinical Trials Clinical Trials Drugs 147

Pharmaceutical Technology

APRIL 10, 2023

The Australian Government’s Department of Health and Aged Care has announced the availability of new medicines for graft versus host disease (GVHD), chronic rhinosinusitis, and oesophageal cancer. Time is of the essence for patients living with GVHD and their caregivers, who have had no other, or limited, treatment options until now.

Medicine 130

Medicine Production 130

pharmaphorum

NOVEMBER 15, 2023

The evolving landscape of medicinal cannabis and its synergy with pharmaceutical giants Nicole.Raleigh Wed, 15/11/2023 - 10:19 Bookmark this

Medicine 124

Medicine 124

Velocity Clinical Research

NOVEMBER 21, 2023

“Without clinical research, there would be little if any development of new medicines,” says Isabelle Schenkenberger, MD. An Internal Medicine Specialist since 2000, Dr. Schenkenberger has practiced at her own clinic since 2002. The post PI Savors Opportunity to Advance Medicine appeared first on Velocity Clinical Research.

Medicine 59

Medicine Cardiology Clinical Trials Clinical Trials 59

Pharmaceutical Technology

NOVEMBER 18, 2023

Amphotericin B is under clinical development by Cystetic Medicines and currently in Phase I for Cystic Fibrosis.

Medicine 100

Medicine Clinical Development Development 100

Pharmaceutical Technology

FEBRUARY 3, 2023

The field of genomic medicine has reached a true turning point. In June 2022, the European Medicines Agency approved an adeno-associated viral (AAV) vector-based therapy for adults with Hemophilia A, making the treatment available to an estimated 3,200 eligible patients. [1] CEVEC became part of Cytiva in October 2022.

Genome 244

Genome Genomics Gene Therapy Medicine 244

Pharmaceutical Technology

JULY 1, 2022

Blueprint Medicines has entered strategic financing partnerships for up to $1.25bn with life sciences-focused investors Sixth Street and Royalty Pharma. Under the deal, Blueprint Medicines will receive an upfront cash payment of $175m as well as up to $165m in potential milestone payments contingent on sales in the future.

Medicine 147

Medicine FDA Approval Life Science Business Development 147

World of DTC Marketing

DECEMBER 4, 2020

Digital medicine has been thrust into the spotlight because of the pandemic and the media hype is in overdrive. A study of some 16m American ones just reported in jama Internal Medicine , a journal, found that their use of telemedicine surged 30-fold between January and June. ” Digital medicine also needs better clarification.

Medicine 201

Medicine Doctors Doctor Pharmacy 201

Bio Pharma Dive

MAY 25, 2022

The new initiative commits Pfizer to supplying current and future branded medicines at lower cost to 45 countries. The pharma has been criticized for not doing enough to make its COVID-19 vaccine and pill available globally.

Medicine 244

Medicine Vaccination Vaccine Sales 244

Pharmaceutical Technology

APRIL 12, 2023

Cognizant and Boehringer Ingelheim are collaborating on an integrated cloud platform to enhance the speed and quality of medicinal therapy development. Cognizant will leverage the Veeva Development Cloud platform to help Boehringer Ingelheim to merge medicinal development processes and data into a connected technology ecosystem.

Medicine 130

Medicine Life Science Clinical Development Development 130

Outsourcing Pharma

NOVEMBER 21, 2023

to discuss a number of issues those working in precision medicine still face. OSP had a discussion with Tracy Curley, CEO of iSpecimen, and Eric Langlois, chief revenue officer of iSpecimen and Michael Howell,founder of Mountaineer Biosciences, Inc.

Medicine 101

Medicine Clinical Development Development 101

Pharmaceutical Technology

AUGUST 11, 2022

Gemini Therapeutics has signed a definitive agreement to merge with Disc Medicine in an all-stock deal to create a clinical-stage biopharmaceutical company. The merged company is expected to be named Disc Medicine, which will have corporate headquarters in Watertown, Massachusetts, US. To back the merger, Disc raised funds worth $53.5m

Medicine 147

Medicine Clinical Trials Clinical Trials Antibody 147

pharmaphorum

OCTOBER 26, 2023

The longitudinal history of medicines innovation: Part One Mike.Hammerton Thu, 26/10/2023 - 09:00 Bookmark this

Medicine 115

Medicine 115

pharmaphorum

SEPTEMBER 19, 2023

The fading generics industry and essential medicine supply Mike.Hammerton Tue, 19/09/2023 - 10:00 Bookmark this

Medicine 134

Medicine 134

pharmaphorum

NOVEMBER 9, 2023

Medicine, Media, Metamorphosis: How M3 is championing medical communications for modern healthcare Mike.Hammerton Thu, 09/11/2023 - 08:00 Bookmark this

Medicine 111

Medicine 111

pharmaphorum

OCTOBER 26, 2023

Sofinnova raises $200m for digital medicine fund Phil.Taylor Thu, 26/10/2023 - 08:06 Bookmark this

Medicine 110

Medicine 110

Pharmaceutical Technology

JANUARY 4, 2023

Belharra Therapeutics and Roche Group member Genentech have announced a partnership for the discovery and development of new small molecule medicines across several therapeutic areas. The post Belharra and Genentech partner for small molecule medicines development appeared first on Pharmaceutical Technology.

Medicine 130

Medicine Development Drugs Sales 130

BioSpace

OCTOBER 19, 2023

Sail Biomedicines combines Laronde’s circular eRNA platform with Senda Biosciences’ nanoparticle delivery technology in the pursuit of a new class of programmable medicines across therapeutic areas.

Medicine 111

Medicine 111